Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of oral ziprasidone in children and adolescents with bipolar I disorder (manic or mixed)
2020-003972-42Phase 3
- Sponsor
- Pfizer
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Ziprasidone flexible-dose with Placebo (2 arms). Primary endpoint: Change from baseline in Young Mania Rating Scale (YMRS) total score to Week 4.
02
Drugs
ziprasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2020-003972-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003972-42.